Matrix metalloproteinases: Contribution to pathogenesis, diagnosis and treatment of periodontal inflammation

References

• Gross J., Lapiere C. M. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci 1962; 48: 1014–22
   PubMed Web of Science ®Google Scholar
• Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827–39
   PubMed Web of Science ®Google Scholar
• Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; b: 161–74
   Google Scholar
• Murphy G., Knäuper V. Relating matrix metalloproteinase structure to function: why the ‘hemopexin’ domain?. Matrix Biol 1997; 15: 511–8
   PubMed Web of Science ®Google Scholar
• McCawley L. J., Matrisian L. M. Matrix metalloproteinases: they're not just for matrix anymore!. Curr Opin Cell Biol 2001; 13: 534–40
   PubMed Web of Science ®Google Scholar
• Ala‐aho R., Kähäri V. ‐M. Collagenases in cancer. Biochimie 2005; 87: 273–86
   PubMed Web of Science ®Google Scholar
• Golub L. M., Wolff M., Roberts S., Lee H. M., Leung M., Payonk G. S. Treating periodontal diseases by blocking tissue‐destructive enzymes. J Am Dent Assoc 1994; 125: 163–9, discussion 169–71
   PubMed Web of Science ®Google Scholar
• Björklund M., Koivunen E. Gelatinase‐mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005; 25: 37–69
   Google Scholar
• Itoh Y., Kajita M., Kinoh H., Mori H., Okada A., Seiki M. Membrane type 4 matrix metallloproteinase (MT4‐MMP, MMP‐17) is a glycosyl‐phosphatidyl inositol‐anchored proteinase. J Biol Chem 1999; 274: 34260–6
   PubMed Web of Science ®Google Scholar
• Kojima S., Itoh Y., Matsumoto S., Masuho Y., Seiki M. Membrane‐type 6 matrix metalloproteinase is the second glycosyl‐phosphatidyl inositol‐anchored MMP. FEBS Lett 2000; 480: 142–6
   PubMed Web of Science ®Google Scholar
• Weiss S. J. Tissue destruction by neutrophils. N Eng J Med 1989; 320: 365–76
   PubMed Web of Science ®Google Scholar
• Ding Y., Uitto V. J., Haapasalo M., Lounatmaa K., Konttinen Y. T., Salo T., et al. Membrane components of Treponema denticola trigger proteinase release from human polymorphonuclear leukocytes. J Dent Res 1996; 75: 1986–93
   PubMed Web of Science ®Google Scholar
• Ding Y., Haapasalo M., Kerosuo E., Lounatmaa K., Kotiranta A., Sorsa T. Release and activation of human neutrophil matrix metallo‐ and serine proteinases during phagocytosis of Fusobacterium nucleatum, Porphyromonas gingivalis and Treponema denticola. J Clin Periodontol 1997; 24: 237–48
   PubMed Web of Science ®Google Scholar
• Weiss S. J., Peppin G., Ortiz X., Ragsdale C., Test S. T. Oxidative autoactivation of latent collagenase by human neutrophils. Science 1985; 227: 747–9
   PubMed Web of Science ®Google Scholar
• Hanemaaijer R., Sorsa T., Konttinen Y. T., Ding Y., Sutinen M., Visser H., et al. Matrix metalloproteinase‐8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor‐alpha and doxycycline. J Biol Chem 1997; 272: 31504–9
   PubMed Web of Science ®Google Scholar
• Saari H., Suomalainen K., Lindy O., Konttinen Y. T., Sorsa T. Activation of latent human neutrophil collagenase by reactive oxygen species and serine proteases. Biochem Biophys Res Commun 1990; 171: 979–87
   PubMed Web of Science ®Google Scholar
• Cole A. A., Kuettner K. E. MMP‐8 (neutrophil collagenase) mRNA and aggrecanase cleavage products are present in normal and osteoarthritic human articular cartilage. Acta Orthop Scand 1995; 98–102
   Google Scholar
• Cole A. A., Chubinskaya S., Schumacher B., Huch K., Szabo G., Yao J., et al. Chondrocyte matrix metalloproteinase‐8. Human articular chondrocytes express neutrophil collagenase. J Biol Chem 1996; 271: 11023–6
   PubMed Web of Science ®Google Scholar
• Chubinskaya S., Huch K., Mikecz K., Cs‐Szabo G., Hasty K. A., Kuettner K. E., et al. Chondrocyte matrix metalloproteinase‐8: up‐regulation of neutrophil collagenase by interleukin‐1 beta in human cartilage from knee and ankle joints. Lab Invest 1996; 74: 232–40
   PubMed Web of Science ®Google Scholar
• Palosaari H., Wahlgren J., Larmas M., Ronka H., Sorsa T., Salo T., et al. The expression of MMP‐8 in human odontoblasts and dental pulp cells is down‐regulated by TGF‐beta1. J Dent Res 2000; 79: 77–84
   PubMed Web of Science ®Google Scholar
• Tervahartiala T., Pirilä E., Ceponis A., Maisi P., Salo T., Tuter G., et al. The in vivo expression of the collagenolytic matrix metalloproteinases (MMP‐2, ‐8, ‐13, and ‐14) and matrilysin (MMP‐7) in adult and localized juvenile periodontitis. J Dent Res 2000; 79: 1969–77
   PubMed Web of Science ®Google Scholar
• Prikk K., Maisi P., Pirilä E., Reintam M. A., Salo T., Sorsa T., et al. Airway obstruction correlates with collagenase‐2 (MMP‐8) expression and activation in bronchial asthma. Lab Invest 2002; 82: 1535–45
   PubMedGoogle Scholar
• Prikk K., Maisi P., Pirila E., Sepper R., Salo T., Wahlgren J., et al. In vivo collagenase‐2 (MMP‐8) expression by human bronchial epithelial cells and monocytes/macrophages in bronchiectasis. J Pathol 2001; 194: 232–8
   PubMed Web of Science ®Google Scholar
• Wahlgren J., Maisi P., Sorsa T., Sutinen M., Tervahartiala T., Pirila E., et al. Expression and induction of collagenases (MMP‐8 and ‐13) in plasma cells associated with bone‐destructive lesions. J Pathol 2001; 194: 217–24
   PubMed Web of Science ®Google Scholar
• Moilanen M., Pirilä E., Grenman R., Sorsa T., Salo T. Expression and regulation of collagenase‐2 (MMP‐8) in head and neck squamous cell carcinomas. J Pathol 2002; 197: 72–81
   PubMedGoogle Scholar
• Bachmeier B. E., Nerlich A. G., Boukamp P., Lichtinghagen R., Tschesche H., Fritz H., et al. Human keratinocyte cell lines differ in the expression of the collagenolytic matrix metalloproteinases‐1,‐8, and ‐13 and of TIMP‐1. Biol Chem 2000; 38: 509–16
   Google Scholar
• Kiili M., Cox S. W., Chen H. Y., Wahlgren J., Maisi P., Eley B. M., et al. Collagenase‐2 (MMP‐8) and collagenase‐3 (MMP‐13) in adult periodontitis: molecular forms and levels in gingival crevicular fluid and immunolocalisation in gingival tissue. J Clin Periodontol 2002; 29: 224–32
   PubMed Web of Science ®Google Scholar
• Sorsa T., Tjäderhane L., Salo T. Matrix metalloproteinases (MMPs) in oral diseases. Oral Dis 2004; 10: 311–8
   PubMed Web of Science ®Google Scholar
• Balbin M., Fueyo A., Tester A. M., Pendas A. M., Pitiot A. S., Astudillo A., et al. Loss of collagenase‐2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003; 35: 252–7
   PubMed Web of Science ®Google Scholar
• Owen C. A., Hu Z., Lopez‐Otin C., Shapiro S. D. Membrane‐bound matrix metalloproteinase‐8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase‐resistant collagenase and serpinase. J Immunol 2004; 172: 7791–803
   PubMed Web of Science ®Google Scholar
• Gueders M. M., Balbin M., Rocks N., Foidart J. M., Gosset P., Louis R., et al. Matrix metalloproteinase‐8 deficiency promotes granulocytic allergen‐induced airway inflammation. J Immunol 2005; 175: 2589–97
   PubMed Web of Science ®Google Scholar
• Freije J. M., Diez‐Itza I., Balbin M., Sanchez L. M., Blasco R., Tolivia J., et al. Molecular cloning and expression of collagenase‐3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994; 269: 16766–73
   PubMed Web of Science ®Google Scholar
• Knäuper V., Lopez‐Otin C., Smith B., Knight G., Murphy G. Biochemical characterization of human collagenase‐3. J Biol Chem 1996; 271: 1544–50
   PubMed Web of Science ®Google Scholar
• Johansson N., Kähäri V. M. Matrix metalloproteinases in squamous cell carcinoma. Histol Histopathol 2000; 15: 225–37
   PubMedGoogle Scholar
• Kähäri V. M., Saarialho‐Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999; 31: 34–45
   PubMed Web of Science ®Google Scholar
• Konttinen Y. T., Salo T., Hanemaaijer R., Valleala H., Sorsa T., Sutinen M., et al. Collagenase‐3 (MMP‐13) and its activators in rheumatoid arthritis: localization in the pannus‐hard tissue junction and inhibition by alendronate. Matrix Biol 1999; 18: 401–12
   PubMed Web of Science ®Google Scholar
• Lindy O., Konttinen Y. T., Sorsa T., Ding Y., Santavirta S., Ceponis A., et al. Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritis Rheum 1997; 40: 1391–9
   PubMed Web of Science ®Google Scholar
• Ylipalosaari M., Thomas G. J., Nystrom M., Salhimi S., Marshall J. F., Huotari V., et al. Alpha v beta 6 integrin down‐regulates the MMP‐13 expression in oral squamous cell carcinoma cells. Exp Cell Res 2005; 309: 273–83
   Google Scholar
• Westerlund U., Ingman T., Lukinmaa P. L., Salo T., Kjeldsen L., Borregaard N., et al. Human neutrophil gelatinase and associated lipocalin in adult and localized juvenile periodontitis. J Dent Res 1996; 75: 1553–63
   PubMed Web of Science ®Google Scholar
• Ma J., Kitti U., Hanemaaijer R., Teronen O. P., Sorsa T. A., Natah S., et al. Gelatinase B is associated with peri‐implant bone loss. Clin Oral Implants Res 2003; 14: 709–13
   PubMed Web of Science ®Google Scholar
• Makela M., Salo T., Uitto V. J., Larjava H. Matrix metalloproteinases (MMP‐2 and MMP‐9) of the oral cavity: cellular origin and relationship to periodontal status. J Dent Res 1994; 73: 1397–406
   PubMed Web of Science ®Google Scholar
• Beklen A., Laine M., Venta I., Hyrkäs T., Konttinen Y. T. Role of TNF‐{alpha} and its receptors in pericoronitis. J Dent Res 2005; 84: 1178–82
   PubMed Web of Science ®Google Scholar
• Beklen A., Tuter G., Sorsa T., Hanemaaijer R., Virtanen I., Tervahartiala T., et al. Gingival tissue and crevicular fluid co‐operation in adult periodontitis. J Dent Res 2006; 85: 59–63
   Web of Science ®Google Scholar
• Ingman T., Tervahartiala T., Ding Y., Tschesche H., Haerian A., Kinane D. F., et al. Matrix metalloproteinases and their inhibitors in gingival crevicular fluid and saliva of periodontitis patients. J Clin Periodontol 1996; 23: 1127–32
   PubMed Web of Science ®Google Scholar
• Seiki M. Membrane‐type matrix metalloproteinases. APMIS 1999; 107: 137–43
   PubMed Web of Science ®Google Scholar
• Knauper V., Will H., Lopez‐Otin C., Smith B., Atkinson S. J., Stanton H., et al. Cellular mechanisms for human procollagenase‐3 (MMP‐13) activation. Evidence that MT1‐MMP (MMP‐14) and gelatinase a (MMP‐2) are able to generate active enzyme. J Biol Chem 1996; 271: 17124–31
   PubMed Web of Science ®Google Scholar
• Holopainen J. M., Moilanen J. A., Sorsa T., Kivela‐Rajamaki M., Tervahartiala T., Vesaluoma M. H., et al. Activation of matrix metalloproteinase‐8 by membrane type 1‐MMP and their expression in human tears after photorefractive keratectomy. Invest Ophthalmol Vis Sci 2003; 44: 2550–6
   PubMed Web of Science ®Google Scholar
• Sekine‐Aizawa Y., Hama E., Watanabe K., Tsubuki S., Kanai‐Azuma M., Kanai Y., et al. Matrix metalloproteinase (MMP) system in brain: identification and characterization of brain‐specific MMP highly expressed in cerebellum. Eur J Neurosci 2001; 13: 935–48
   PubMed Web of Science ®Google Scholar
• Matsuda A., Itoh Y., Koshikawa N., Akizawa T., Yana I., Seiki M. Clusterin, an abundant serum factor, is a possible negative regulator of MT6‐MMP/MMP‐25 produced by neutrophils. J Biol Chem 2003; 278: 36350–7
   Google Scholar
• Drew A. F., Blick T. J., Lafleur M. A., Tim E. L., Robbie M. J., Rice G. E., et al. Correlation of tumor‐ and stromal‐derived MT1‐MMP expression with progression of human ovarian tumors in SCID mice. Gynecol Oncol 2004; 95: 437–48
   Google Scholar
• Toft‐Hansen H., Nuttall R. K., Edwards D. R., Owens T. Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis. J Immunol 2004; 173: 5209–18
   PubMed Web of Science ®Google Scholar
• Nie J., Pei D. Rapid inactivation of alpha‐1‐proteinase inhibitor by neutrophil specific leukolysin/membrane‐type matrix metalloproteinase 6. Exp Cell Res 2004; 296: 145–50
   Google Scholar
• Nie J., Pei D. Direct activation of pro‐matrix metalloproteinase‐2 by leukolysin/membrane‐type 6 matrix metalloproteinase/matrix metalloproteinase 25 at the asn(109)‐Tyr bond. Cancer Res 2003; 63: 6758–62
   PubMed Web of Science ®Google Scholar
• Emingil G., Kuula H., Sorsa T., Atilla G. Gingival crevicular fluid matrix metalloproteinase‐25 and ‐26 levels in periodontal disease. J Periodontol 2006; 77: 664–71
   Google Scholar
• Kazes I., Delarue F., Hagege J., Bouzhir‐Sima L., Rondeau E., Sraer J. D., et al. Soluble latent membrane‐type 1 matrix metalloprotease secreted by human mesangial cells is activated by urokinase. Kidney Int 1998; 54: 1976–84
   PubMed Web of Science ®Google Scholar
• Li H., Bauzon D. E., Xu X., Tschesche H., Cao J., Sang Q. A. Immunological characterization of cell‐surface and soluble forms of membrane type 1 matrix metalloproteinase in human breast cancer cells and in fibroblasts. Mol Carcinog 1998; 22: 84–94
   Google Scholar
• Cox S. W., Eley B. M., Kiili M., Asikainen A., Tervahartiala T., Sorsa T. Collagen degradation by interleukin‐1β‐stimulated gingival fibroblasts is accompanied by release and activation of multiple matrix metalloproteinases and cysteine proteinases. Oral Dis 2006; 12: 34–40
   PubMed Web of Science ®Google Scholar
• Maisi P., Prikk K., Sepper R., Pirilä E., Salo T., Hietanen J., et al. Soluble membrane‐type 1 matrix metalloproteinase (MT1‐MMP) and gelatinase A (MMP‐2) in induced sputum and bronchoalveolar lavage fluid of human bronchial asthma and bronchiectasis. APMIS 2002; 110: 771–82
   PubMed Web of Science ®Google Scholar
• Folgueras A. R., Pendas A. M., Sanchez L. M., Lopez‐Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004; 48: 411–24
   PubMed Web of Science ®Google Scholar
• Baker A. H., Zaltsman A. B., George S. J., Newby A. C. Divergent effects of tissue inhibitor of metalloproteinase‐1, ‐2, or ‐3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP‐3 promotes apoptosis. J Clin Invest 1998; 101: 1478–87
   PubMed Web of Science ®Google Scholar
• Woessner J. F., Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145–54
   PubMed Web of Science ®Google Scholar
• Shibutani T., Yamashita K., Aoki T., Iwayama Y., Nishikawa T., Hayakawa T. Tissue inhibitors of metalloproteinases (TIMP‐1 and TIMP‐2) stimulate osteoclastic bone resorption. J Bone Miner Metab 1999; 17: 245–51
   Google Scholar
• Sobue T., Hakeda Y., Kobayashi Y., Hayakawa H., Yamashita K., Aoki T., et al. Tissue inhibitor of metalloproteinases 1 and 2 directly stimulate the bone‐resorbing activity of isolated mature osteoclasts. J Bone Miner Res 2001; 16: 2205–14
   Web of Science ®Google Scholar
• Uitto V. J., Overall C. M., McCulloch C. Proteolytic host cell enzymes in gingival crevice fluid. Periodontol 2000 2003; 31: 77–104
   PubMed Web of Science ®Google Scholar
• Birkedal‐Hansen H. Role of matrix metalloproteinases in human periodontal diseases. J Periodontol 1993; 64: 474–84
   PubMed Web of Science ®Google Scholar
• Julovi S. M., Yasuda T., Shimizu M., Hiramitsu T., Nakamura T. Inhibition of interleukin‐1beta‐stimulated production of matrix metalloproteinases by hyaluronan via CD44 in human articular cartilage. Arthritis Rheum 2004; 50: 516–25
   PubMedGoogle Scholar
• Liacini A., Sylvester J., Li W. Q., Huang W., Dehnade F., Ahmad M., et al. Induction of matrix metalloproteinase‐13 gene expression by TNF‐alpha is mediated by MAP kinases, AP‐1, and NF‐kappaB transcription factors in articular chondrocytes. Exp Cell Res 2003; 288: 208–17
   PubMed Web of Science ®Google Scholar
• Damiens C., Fortun Y., Charrier C., Heymann D., Padrines M. Modulation by soluble factors of gelatinase activities released by osteoblastic cells. Cytokine 2000; 12: 1727–31
   Google Scholar
• Johnson L. L., Dyer R., Hupe D. J. Matrix metalloproteinases. Curr Opin Chem Biol 1998; 2: 466–71
   PubMed Web of Science ®Google Scholar
• Sorsa T., Salo T., Koivunen E., Tyynela J., Konttinen Y. T., Bergmann U., et al. Activation of type IV procollagenases by human tumor‐associated trypsin‐2. J Biol Chem 1997; 272: 21067–74
   PubMed Web of Science ®Google Scholar
• Moilanen M., Sorsa T., Stenman M., Nyberg P., Lindy O., Vesterinen J., et al. Tumor‐associated trypsinogen‐2 (trypsinogen‐2) activates procollagenases (MMP‐1, ‐8, ‐13) and stromelysin‐1 (MMP‐3) and degrades type I collagen. Biochemistry 2003; 42: 5414–20
   PubMed Web of Science ®Google Scholar
• Stenman M., Ainola M., Valmu L., Bjartell A., Ma G., Stenman U. H., et al. Trypsin‐2 degrades human type II collagen and is expressed and activated in mesenchymally transformed rheumatoid arthritis synovitis tissue. Am J Pathol 2005; 167: 1119–24
   PubMed Web of Science ®Google Scholar
• Sorsa T., Ingman T., Suomalainen K., Haapasalo M., Konttinen Y. T., Lindy O., et al. Identification of proteases from periodontopathogenic bacteria as activators of latent human neutrophil and fibroblast‐type interstitial collagenases. Infect Immun 1992; 60: 4491–5
   PubMed Web of Science ®Google Scholar
• Okamoto T., Akuta T., Tamura F., van Der Vliet A., Akaike T. Molecular mechanism for activation and regulation of matrix metalloproteinases during bacterial infections and respiratory inflammation. Biol Chem 2004; 385: 997–1006
   PubMed Web of Science ®Google Scholar
• Potempa J., Banbula A., Travis J. Role of bacterial proteinases in matrix destruction and modulation of host responses. Periodontol 2000 2000; 24: 153–92
   PubMed Web of Science ®Google Scholar
• Bannikov G. A., Karelina T. V., Collier I. E., Marmer B. L., Goldberg G. I. Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide. J Biol Chem 2002; 277: 16022–7
   PubMed Web of Science ®Google Scholar
• Fedarko N. S., Jain A., Karadag A., Fisher L. W. Three small integrin binding ligand N‐linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB J 2004; 18: 734–6
   PubMed Web of Science ®Google Scholar
• Sorsa T., Ding Y. L., Ingman T., Salo T., Westerlund U., Haapasalo M., et al. Cellular source, activation and inhibition of dental plaque collagenase. J Clin Periodontol 1995; 22: 709–17
   PubMed Web of Science ®Google Scholar
• McMillan S. J., Kearley J., Campbell J. D., Zhu X. W., Larbi K. Y., Shipley J. M., et al. Matrix metalloproteinase‐9 deficiency results in enhanced allergen‐induced airway inflammation. J Immunol 2004; 172: 2586–94
   PubMed Web of Science ®Google Scholar
• Sternlicht M. D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463–516
   PubMed Web of Science ®Google Scholar
• Fini M. E., Cook J. R., Mohan R., Brinckerhoff C. E. Regulation of matrix metalloproteinase gene expression. Matrix metalloproteinases, W. C Parks, R. P Mecham. Academic Press, California 1998; 299–356
   Google Scholar
• Shrivastava A., Radziejewski C., Campbell E., Zhu X. W., Larbi K. Y., Shipley J. M., et al. An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Mol Cell 1997; 1: 25–34
   PubMed Web of Science ®Google Scholar
• Vogel W., Gish G. D., Alves F., Pawson T. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell 1997; 1: 13–23
   PubMed Web of Science ®Google Scholar
• Uria J. A., Jimenez M. G., Balbin M., Freije J. M., Lopez‐Otin C. Differential effects of transforming growth factor‐beta on the expression of collagenase‐1 and collagenase‐3 in human fibroblasts. J Biol Chem 1998; 273: 9769–77
   PubMed Web of Science ®Google Scholar
• Opdenakker G., Van den Steen P. E., Dubois B., Nelissen I., Van Coillie E., Masure S., et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2001; 69: 851–9
   PubMed Web of Science ®Google Scholar
• Peppin G. J., Weiss S. J. Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils. Proc Natl Acad Sci U S A 1986; 83: 4322–6
   PubMed Web of Science ®Google Scholar
• Rutter J. L., Mitchell T. I., Buttice G., Meyers J., Gusella J. F., Ozelius L. J., et al. A single nucleotide polymorphism in the matrix metalloproteinase‐1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998; 58: 5321–5
   PubMed Web of Science ®Google Scholar
• Noll W. W., Belloni D. R., Rutter J. L., Storm C. A., Schned A. R., Titus‐Ernstoff L., et al. Loss of heterozygosity on chromosome 11q22‐23 in melanoma is associated with retention of the insertion polymorphism in the matrix metalloproteinase‐1 promoter. Am J Pathol 2001; 158: 691–7
   PubMed Web of Science ®Google Scholar
• Shimajiri S., Arima N., Tanimoto A., Murata Y., Hamada T., Wang K. Y., et al. Shortened microsatellite d(CA)21 sequence down‐regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett 1999; 455: 70–4
   PubMed Web of Science ®Google Scholar
• Przybylowska K., Zielinska J., Zadrozny M., Krawczyk T., Kulig A., Wozniak P., et al. An association between the matrix metalloproteinase 1 promoter gene polymorphism and lymph node metastasis in breast cancer. J Exp Clin Cancer Res 2004; 23: 121–5
   PubMed Web of Science ®Google Scholar
• Kanamori Y., Matsushima M., Minaguchi T., Kobayashi K., Sagae S., Kudo R., et al. Correlation between expression of the matrix metalloproteinase‐1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res 1999; 59: 4225–7
   PubMed Web of Science ®Google Scholar
• Thiry‐Blaise L. M., Taquet A. N., Reginster J. Y., Nusgens B., Franchimont P., Lapiere C. M. Investigation of the relationship between osteoporosis and the collagenase gene by means of polymorphism of the 5'upstream region of this gene. Calcif Tissue Int 1995; 56: 88–91
   Google Scholar
• de Souza A. P., Trevilatto P. C., Scarel‐Caminaga R. M., Brito R. B., Line S. R. MMP‐1 promoter polymorphism: association with chronic periodontitis severity in a Brazilian population. J Clin Periodontol 2003; 30: 154–8
   Google Scholar
• Santos M. C. L., Campos M. I. G., de Souza A. P., Trevilatto P. C., Line S. R. Analysis of MMP‐1 and MMP‐9 promoter polymorphism in early osseointegrated implant failure. Int J Maxillofac Implants 2004; 19: 38–43
   Google Scholar
• Cao Z., Li C., Jin L., Corbet E. F. Association of matrix metalloproteinase‐1 promoter polymorphism with generalized aggressive periodontitis in a Chinese population. J Periodontal Res 2005; 40: 427–31
   Google Scholar
• Itagaki M., Kubota T., Tai H., Shimada Y., Morozumi T., Yamazaki K. Matrix metalloproteinase‐1 and ‐3 gene promoter polymorphisms in Japanese patients with periodontitis. J Clin Periodontol 2004; 31: 764–9
   PubMedGoogle Scholar
• Holla L. I., Jurajda M., Fassmann A., Dvorakova N., Znojil V., Vacha J. Genetic variations in the matrix metalloproteinase‐1 promoter and risk of susceptibility and/or severity of chronic periodontitis in the Czech population. J Clin Periodontol 2004; 31: 685–90
   Google Scholar
• Zhang B., Ye S., Herrmann S. M., Eriksson P., de Maat M., Evans A., et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999; 99: 1788–94
   PubMed Web of Science ®Google Scholar
• Wang J., Warzecha D., Wilcken D., Wang X. L. Polymorphism in the gelatinase B gene and the severity of coronary arterial stenosis. Clin Sci (Lond) 2001; 101: 87–92
   PubMed Web of Science ®Google Scholar
• Fiotti N., Zivadinov R., Altamura N., Nasuelli D., Bratina A., Tommasi M. A., et al. MMP‐9 microsatellite polymorphism and multiple sclerosis. J Neuroimmunol 2004; 152: 147–53
   PubMedGoogle Scholar
• Wagner S., Kluge B., Koziol J. A., Grau A. J., Grond‐Ginsbach C. MMP‐9 polymorphisms are not associated with spontaneous cervical artery dissection. Stroke 2004; 35: e62–4
   Web of Science ®Google Scholar
• Nelissen I., Vandenbroeck K., Fiten P., Hillert J., Olsson T., Marrosu M. G., et al. Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis. J Neuroimmunol 2000; 105: 58–63
   Google Scholar
• Peters D. G., Kassam A., St Jean P. L., Yonas H., Ferrell R. E. Functional polymorphism in the matrix metalloproteinase‐9 promoter as a potential risk factor for intracranial aneurysm. Stroke 1999; 30: 2612–6
   PubMed Web of Science ®Google Scholar
• de Souza A. P., Trevilatto P. C., Scarel‐Caminaga R. M., de Brito R. B., Jr., Barros S. P., Line S. R. Analysis of the MMP‐9 (C‐1562 T) and TIMP‐2 (G‐418C) gene promoter polymorphisms in patients with chronic periodontitis. J Clin Periodontol 2005; 32: 207–11
   PubMed Web of Science ®Google Scholar
• Ye S., Watts G. F., Mandalia S., Humphries S. E., Henney A. M. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995; 73: 209–15
   PubMedGoogle Scholar
• de Maat M. P., Jukema J. W., Ye S., Zwinderman A. H., Moghaddam P. H., Beekman M., et al. Effect of the stromelysin‐1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol 1999; 83: 852–6
   PubMed Web of Science ®Google Scholar
• Terashima M., Akita H., Kanazawa K., Inoue N., Yamada S., Ito K., et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 1999; 99: 2717–9
   PubMed Web of Science ®Google Scholar
• Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 2000; 19: 623–9
   PubMed Web of Science ®Google Scholar
• Holla L. I., Fassmann A., Vasku A., Goldbergova M., Beranek M., Znojil V., et al. Genetic variations in the human gelatinase A (matrix metalloproteinase‐2) promoter are not associated with susceptibility to, and severity of, chronic periodontitis. J Periodontol 2005; 76: 1056–60
   Google Scholar
• Kinane D. F., Shiba H., Hart T. C. The genetic basis of periodontitis. Periodontol 2000 2005; 39: 91–117
   PubMedGoogle Scholar
• Loos B. G., John R. P., Laine M. L. Identification of genetic risk factors for periodontitis and possible mechanisms of action. J Clin Periodontol 2005; 32: 159–79
   PubMed Web of Science ®Google Scholar
• Ryan M. E., Carnu O., Kamer A. The influence of diabetes on periodontal tissues. J Amer Dent Assoc 2003; 134: 395–405
   Google Scholar
• Meurman J. H., Janket S. J., Qvarnstrom M., Nuutinen P. Dental infections and serum inflammatory markers in patients with and without severe heart disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 96: 695–700
   PubMed Web of Science ®Google Scholar
• Zhou Z., Apte S. S., Soininen R., Cao R., Baaklini G. Y., Rauser R. W., et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane‐type matrix metalloproteinase I. Proc Natl Acad Sci U S A 2000; 97: 4052–7
   PubMed Web of Science ®Google Scholar
• Milner J. M., Cawston T. E. Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases. Curr Drug Targets Inflamm Allergy 2005; 4: 363–75
   PubMedGoogle Scholar
• Sorsa T., Tervahartiala T., Stenman M., Suomalainen K., Mäntylä P. Chair‐side diagnostic point‐of‐care MMP tools in periodontitis and peri‐implantitis. Nordic Dentistry. Quintessence Int, Schou L, Copenhagen 2004; 79–95
   Google Scholar
• Sorsa T., Mantyla P., Ronka H., Kallio P., Kallis G. B., Lundqvist C., et al. Scientific basis of a matrix metalloproteinase‐8 specific chair‐side test for monitoring periodontal and peri‐implant health and disease. Ann N Y Acad Sci 1999; 878: 130–40
   PubMed Web of Science ®Google Scholar
• Sorsa T., Uitto V. J., Suomalainen K., Vauhkonen M., Lindy S. Comparison of interstitial collagenases from human gingiva, sulcular fluid and polymorphonuclear leukocytes. J Periodontal Res 1988; 23: 386–93
   PubMed Web of Science ®Google Scholar
• Sorsa T., Suomalainen K., Uitto V. J. The role of gingival crevicular fluid and salivary interstitial collagenases in human periodontal diseases. Arch Oral Biol 1990; 35: 193S–196S
   Google Scholar
• Sorsa T., Ding Y., Salo T., Lauhio A., Teronen O., Ingman T., et al. Effects of tetracyclines on neutrophil, gingival, and salivary collagenases. A functional and western‐blot assessment with special reference to their cellular sources in periodontal diseases. Ann N Y Acad Sci 1994; 732: 112–31
   PubMed Web of Science ®Google Scholar
• Kivelä‐Rajamäki M. J., Teronen O. P., Maisi P., Husa V., Tervahartiala T. I., Pirila E. M., et al. Laminin‐5 gamma2‐chain and collagenase‐2 (MMP‐8) in human peri‐implant sulcular fluid. Clin Oral Implants Res 2003; 14: 158–65
   PubMed Web of Science ®Google Scholar
• Kivelä‐Rajamäki M., Maisi P., Srinivas R., Tervahartiala T., Teronen O., Husa V., et al. Levels and molecular forms of MMP‐7 (matrilysin‐1) and MMP‐8 (collagenase‐2) in diseased human peri‐implant sulcular fluid. J Periodontal Res 2003; 38: 583–90
   PubMed Web of Science ®Google Scholar
• Golub L. M., Lee H. M., Ryan M. E., Giannobile W. V., Payne J., Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non‐antimicrobial mechanisms. Adv Dent Res 1998; 12: 12–26
   PubMedGoogle Scholar
• Preshaw P. M., Hefti A. F., Jepsen S., Etienne D., Walker C., Bradshaw M. H. Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. A review. J Clin Periodontol 2004; 31: 697–707
   PubMed Web of Science ®Google Scholar
• Coussens L. M., Fingleton B., Matrisian L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387–92
   PubMed Web of Science ®Google Scholar
• Koivunen E., Arap W., Valtanen H., Rainisalo A., Medina O. P., Heikkila P., et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999; 17: 768–74
   PubMed Web of Science ®Google Scholar
• Bjornsson M. J., Havemose‐Poulsen A., Stoltze K., Holmstrup P. Influence of the matrix metalloproteinase inhibitor batimastat (BB‐94) on periodontal bone destruction in Sprague‐Dawley rats. J Periodontal Res 2004; 39: 269–74
   Google Scholar
• Sorsa T., Golub L. M. Is the excessive inhibition of matrix metalloproteinases (MMPs) by potent synthetic MMP inhibitors (MMPIs) desirable in periodontitis and other inflammatory diseases? That is: ‘Leaky’ MMPIs vs excessively efficient drugs. Oral Dis 2005; 11: 408–9
   PubMed Web of Science ®Google Scholar
• Ashley R. A. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. SDD Clinical Research Team. Ann N Y Acad Sci 1999; 878: 335–46
   PubMed Web of Science ®Google Scholar
• Craig R. G., Yip J. K., So M. K., Boylan R. J., Socransky S. S., Haffajee A. D. Relationship of destructive periodontal disease to the acute‐phase response. J Periodontol 2003; 74: 1007–16
   PubMed Web of Science ®Google Scholar
• D'Aiuto F., Parkar M., Andreou G., Suvan J., Brett P. M., Ready D., et al. Periodontitis and systemic inflammation: control of the local infection is associated with a reduction in serum inflammatory markers. J Dent Res 2004; 83: 156–60
   PubMed Web of Science ®Google Scholar
• Golub L. M., Payne J. B., Reinhardt R. A., Nieman G. Can systemic diseases co‐induce (not just exacerbate) periodontitis. A hypothetical ‘two‐hit’ model. J Dent Res 2006; 85: 102–05
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Rifai N., Rose L., Buring J. E., Cook N. R. Comparison of C‐reactive protein and low‐density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557–65
   PubMed Web of Science ®Google Scholar
• Blankenberg S., Rupprecht H. J., Poirier O., Bickel C., Smieja M., Hafner G., et al. AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579–85
   PubMed Web of Science ®Google Scholar
• Brown D. L., Desai K. K., Vakili B. A., Nouneh C., Lee H. M., Golub L. M. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 2004; 24: 733–8
   PubMed Web of Science ®Google Scholar
• Brown D. L., Golub L. M., Lee H. M., Desai K., Sorsa T., Greenwald R. Effect of sub‐antimicrobial doxycycline on biomarkers in patients with acute coronary syndromes. J Dent Res 2003; 82, abstract 1443
   Google Scholar
• Eley B. M., Cox S. W. Advances in periodontal diagnosis. 8. Commercial diagnostic kits based on GCF proteolytic and hydrolytic enzyme levels. Br Dent J 1998; 184b: 373–6
   Google Scholar
• Mantyla P., Stenman M., Kinane D. F., Tikanoja S., Luoto H., Salo T., et al. Gingival crevicular fluid collagenase‐2 (MMP‐8) test stick for chair‐side monitoring of periodontitis. J Periodontal Res 2003; 38: 436–9
   PubMed Web of Science ®Google Scholar
• Golub L. M., Lee H. M., Greenwald R. A., Ryan M. E., Sorsa T., Salo T., et al. A matrix metalloproteinase inhibitor reduces bone‐type collagen degradation fragments and specific collagenases in gingival crevicular fluid during adult periodontitis. Inflamm Res 1997; 46: 310–9
   PubMed Web of Science ®Google Scholar
• Emingil G., Atilla G., Sorsa T., Luoto H., Kirilmaz L., Baylas H. The effect of adjunctive low‐dose doxycycline therapy on clinical parameters and gingival crevicular fluid matrix metalloproteinase‐8 levels in chronic periodontitis. J Periodontol 2004; 75: 106–15
   PubMed Web of Science ®Google Scholar
• Ryan M. E., Ramamurthy S., Golub L. M. Matrix metalloproteinases and their inhibition in periodontal treatment. Curr Opin Periodontol 1996; 3: 85–96
   PubMedGoogle Scholar
• Apajalahti S., Sorsa T., Railavo S., Ingman T. The in vivo levels of matrix metalloproteinase‐1 and ‐8 in gingival crevicular fluid during initial orthodontic tooth movement. J Dent Res 2003; 82: 1018–22
   PubMed Web of Science ®Google Scholar
• Ingman T., Apajalahti S., Mantyla P., Savolainen P., Sorsa T. Matrix metalloproteinase‐1 and ‐8 in gingival crevicular fluid during orthodontic tooth movement: a pilot study during 1 month of follow‐up after fixed appliance activation. Eur J Orthod 2005; 27b: 202–7
   Google Scholar
• Lauhio A., Salo T., Ding Y., Konttinen Y. T., Nordstrom D., Tschesche H., et al. In vivo inhibition of human neutrophil collagenase (MMP‐8) activity during long‐term combination therapy of doxycycline and non‐steroidal anti‐inflammatory drugs (NSAID) in acute reactive arthritis. Clin Exp Immunol 1994; 98: 21–8
   PubMed Web of Science ®Google Scholar
• Lauhio A., Salo T., Tjaderhane L., Lahdevirta J., Golub L. M., Sorsa T. Tetracyclines in treatment of rheumatoid arthritis. Lancet 1995; 346: 645–6
   PubMed Web of Science ®Google Scholar
• Fingleton B., Menon R., Carter K. J., Overstreet P. D., Hachey D. L., Matrisian L. M., et al. Proteinase activity in human and murine saliva as a biomarker for proteinase inhibitor efficacy. Clin Cancer Res 2004; 10: 7865–74
   Google Scholar
• Nordstrom D., Lindy O., Lauhio A., Sorsa T., Santavirta S., Konttinen Y. T. Anti‐collagenolytic mechanism of action of doxycycline treatment in rheumatoid arthritis. Rheumatol Int 1998; 17: 175–80
   PubMed Web of Science ®Google Scholar
• Valleala H., Teronen O., Friman C., Sorsa T., Solovieva S., Konttinen Y. T. Inhibition of collagenase by a bisphosphonate‐group drug in patients with rheumatoid arthritis. J Rheumatol 2000; 27: 1570–2
   Google Scholar
• Määttä M., Kari O., Tervahartiala T., Peltonen S., Kari M., Saari M., et al. Tear fluid levels of MMP‐8 are elevated in ocular rosacea‐modulation by oral doxycycline. Graefes Arch Clin Exp Ophtalmol 2006; 13: 1–6
   Google Scholar
• Agarwal D., Goodison S., Nicholson B., Tarin D., Urquidi V. Expression of matrix metalloproteinase 8 (MMP‐8) and tyrosinase‐related protein‐1 (TYRP‐1) correlates with the absence of metastasis in an isogenic human breast cancer model. Differentiation 2003; 71: 114–25
   PubMed Web of Science ®Google Scholar
• Elkington P. T., O'Kane C. M., Friedland J. S. The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol 2005; 142: 12–20
   PubMed Web of Science ®Google Scholar